Key facts
- Notable investors include ARCH Venture Partners, MonTEC (Accelerator).
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Big Sur Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Big Sur Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Big Sur Bio
Developer of therapeutics intended to reverse detrimental aspects of aging, particularly those involving poor immune responses, increased inflammation, and certain cancers. The company offers products and services focused on biotechnology services to address age-related health challenges, enabling improved immune function and reduced inflammation for healthier aging.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2024
- Website
- bigsurbio.com/
- Ownership
- Privately Held (backing)
Big Sur Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Big Sur Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Big Sur Bio in its N-PORT filings yet. We sweep new filings monthly.